Jairam Vikram, Park Henry S, Yu James B, Bindra Ranjit S, Contessa Joseph N, Jethwa Krishan R
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut.
Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University School of Medicine, New Haven, Connecticut.
Adv Radiat Oncol. 2022 Mar 21;7(4):100949. doi: 10.1016/j.adro.2022.100949. eCollection 2022 Jul-Aug.
Whole brain radiation therapy (WBRT) is often used as an effective treatment for patients with brain metastasis, although it is also known to have deleterious cognitive effects. Multiple trials have identified strategies to help mitigate neurocognitive decline after WBRT, although there may be barriers to integrating these techniques into routine clinical practice. The aim of this study was to characterize national practice patterns related to neurocognitive preservation strategies used during WBRT.
We conducted an online survey of all American Society for Radiation Oncology-registered radiation oncologists (ROs), excluding trainees, regarding their practice patterns and attitudes toward employing memantine and hippocampal avoidance whole brain radiation therapy (HA-WBRT). Pearson χ tests for categorical variables or Student tests for continuous variables were used to assess associations between provider characteristics and prescribing of either memantine or HA. All statistical tests were 2-sided and a value <.05 was considered statistically significant.
Among 4408 ROs invited to participate, 417 (9.5%) completed the survey. Among respondents, 79.6% reported having offered memantine, 72.7% HA-WBRT, and 63.1% both for any of their patients undergoing WBRT. Common reasons for not offering memantine included limitations of current evidence (35.3%) and concerns about adverse effects (22.4%). Common reasons for not offering HA-WBRT included resource-intensive treatment planning and treatment delay (43.9%) and concern about obtaining prior authorization (38.6%). ROs with fewer years in practice (mean 15.7 vs 23.4 years) were more likely to prescribe memantine ( < .001), whereas HA was more likely prescribed by central nervous system specialists ( < .001) and ROs in academic settings ( = .04).
Our survey suggests that the majority of respondents offer approaches for neurocognitive preservation during WBRT for their patients. Further efforts are needed to broaden education and reduce barriers among ROs to improve implementation of neurocognitive-sparing techniques in patients undergoing WBRT.
全脑放射治疗(WBRT)通常被用作脑转移患者的有效治疗方法,尽管其也具有有害的认知效应。多项试验已确定有助于减轻WBRT后神经认知功能衰退的策略,尽管将这些技术纳入常规临床实践可能存在障碍。本研究的目的是描述与WBRT期间使用的神经认知保护策略相关的全国实践模式。
我们对所有美国放射肿瘤学会注册的放射肿瘤学家(ROs)进行了一项在线调查,不包括实习生,内容涉及他们对使用美金刚和海马回避全脑放射治疗(HA-WBRT)的实践模式和态度。使用分类变量的Pearson χ检验或连续变量的Student检验来评估提供者特征与美金刚或HA处方之间的关联。所有统计检验均为双侧检验,P值<.05被认为具有统计学意义。
在受邀参与的4408名ROs中,417名(9.5%)完成了调查。在受访者中,79.6%报告曾为其接受WBRT的任何患者提供美金刚,72.7%提供HA-WBRT,63.1%两者都提供。不提供美金刚的常见原因包括当前证据的局限性(35.3%)和对不良反应的担忧(22.4%)。不提供HA-WBRT的常见原因包括资源密集型治疗计划和治疗延迟(43.9%)以及对获得事先批准的担忧(38.6%)。从业年限较少的ROs(平均15.7年对23.4年)更有可能开美金刚处方(P<.001),而中枢神经系统专家(P<.001)和学术机构的ROs(P=.04)更有可能开HA处方。
我们的调查表明,大多数受访者为其患者提供WBRT期间的神经认知保护方法。需要进一步努力扩大教育范围并减少ROs之间的障碍,以改善在接受WBRT的患者中实施神经认知保护技术的情况。